<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215328</url>
  </required_header>
  <id_info>
    <org_study_id>USC HS-13-00748</org_study_id>
    <nct_id>NCT04215328</nct_id>
  </id_info>
  <brief_title>Facilitated Release of Endogenous Enterokines</brief_title>
  <acronym>F2G</acronym>
  <official_title>Facilitated Release of Endogenous Enterokines: An Ambulatory Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Halyard Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wallace H. Coulter Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to develop therapy for obesity and diabetes that is as effective as&#xD;
      gastric bypass surgery but without the cost and safety concerns.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric bypass leads to rapid, sustained diabetes remission in the majority of patients who&#xD;
      undergo this procedure and is also highly effective therapy for obesity. However, currently&#xD;
      &lt;1% of medically-eligible patients undergo this or other bariatric operations due to cost and&#xD;
      safety concerns. The approach is based on data suggesting that the benefit of gastric bypass&#xD;
      is largely due to anatomical rearrangement of the intestine which leads to accelerated&#xD;
      delivery of nutrients to the jejunum. This rerouting of nutrients stimulates the release of&#xD;
      multiple neural, hormonal and enterokine responses that are associated with appetite&#xD;
      suppression and improved glucose control. In this pilot proposal the question under&#xD;
      investigation is whether repeated rapid delivery of a mixed meal directly to the jejunum can&#xD;
      promote weight loss and glucose control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2014</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight change between groups</measure>
    <time_frame>Day 0 to Day 14</time_frame>
    <description>Weight measured in kilograms taken before and immediately following the intervention period between the intervention and control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caloric intake within and between groups</measure>
    <time_frame>Day 0 to Day 14</time_frame>
    <description>Caloric intake measured in kcal. Determined by consumption of provided food.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change within group</measure>
    <time_frame>Day 0 to Day 14</time_frame>
    <description>Weight measured in kilgrams. Within group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist and hip measurements</measure>
    <time_frame>Day 0 to Day 14</time_frame>
    <description>Measured in centimeters. Between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>Day 0 to Day 14</time_frame>
    <description>Measured in mmHg for both. Between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Day 0 to Day 14</time_frame>
    <description>Measured in beats per minute. Between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gut hormone levels</measure>
    <time_frame>Day 0 to Day 14</time_frame>
    <description>Including GLP-1, PYY, CCK, C-peptide, and insulin. Between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Mixed-Meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ensure Nutrition Shake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electrolyte Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pedialyte Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mixed-Meal</intervention_name>
    <description>Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses</description>
    <arm_group_label>Mixed-Meal</arm_group_label>
    <other_name>Ensure Nutrition Shake® (Abbott Park, Illinois, U.S.A.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Electrolyte Solution</intervention_name>
    <description>Electrolyte Solution 500mLs by tube daily in 4 doses</description>
    <arm_group_label>Electrolyte Solution</arm_group_label>
    <other_name>Unflavored Pedialyte ® (Abbott Park, Illinois, U.S.A.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes on oral antidiabetic medication&#xD;
&#xD;
          -  BMI greater than or equal to 30kg/m2&#xD;
&#xD;
          -  A1C less than 9%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any of the following medications: dipeptide-peptidase IV (DPP-IV) inhibitors&#xD;
             (e.g., sitagliptin), GLP-1 analogs (e.g., exenatide) or medication that could alter&#xD;
             glucose tolerance (e.g. steroids)&#xD;
&#xD;
          -  Contraindication to tube (e.g. Prior upper gastrointestinal bleed, or history of easy&#xD;
             bleeding, altered foregut anatomy due to obstruction or surgery)&#xD;
&#xD;
          -  Known cardiovascular disease other than controlled hypertension.&#xD;
&#xD;
          -  Pregnancy or unwilling to take contraception&#xD;
&#xD;
          -  Active esophagitis&#xD;
&#xD;
          -  Known hiatal hernia&#xD;
&#xD;
          -  Active gastric ulcer and/or duodenal ulcers,&#xD;
&#xD;
          -  Previous restrictive surgery of the gastrointestinal tract&#xD;
&#xD;
          -  Crohn's disease&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  History of gastrointestinal hemorrhage&#xD;
&#xD;
          -  Known upper gastrointestinal lesions with potential to bleed&#xD;
&#xD;
          -  Use of NSAIDs or anticoagulants&#xD;
&#xD;
          -  Psychiatric disorders other than mild depression&#xD;
&#xD;
          -  Likely inability to adhere to study protocol including alcohol or drug dependent&#xD;
             patients&#xD;
&#xD;
          -  Type I diabetes,&#xD;
&#xD;
          -  Liver, kidney or multi-organ dysfunction.&#xD;
&#xD;
          -  Known eating disorders&#xD;
&#xD;
          -  Inability to attend scheduled or unanticipated study visits&#xD;
&#xD;
          -  Known prior abdominal problems or operations that could lead to adhesions or&#xD;
             strictures and that could prevent the spontaneous passage of a 10 French jejunal tube&#xD;
             if it were to dislodge distally.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Beale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California, Keck School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roybal Diabetes Management Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 26, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Elizabeth Beale</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Nutrient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT04215328/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

